MétaCan
Menu
← Back to cohort
Record W4410941170 · doi:10.1101/2025.05.30.25328679

Global Transportability of Clinical Trial Outcomes to Real-World Lung Cancer Populations A case Study using Lung-MAP S1400I

2025· preprint· en· W4410941170 on OpenAlexaff
Alind Gupta, Nicholas Latimer, Manuel Gomes, Kelvin Chan, Seamus Kent, Stephen Duffield, Sreeram V Ramagopalan, Eran Bendavid, Winson Y. Cheung, Vivek Subbiah, Paul Arora

Bibliographic record

VenuemedRxiv · 2025
Typepreprint
Languageen
FieldMedicine
TopicLung Cancer Treatments and Mutations
Canadian institutionsUniversity of CalgaryHealth Sciences CentreSunnybrook Health Science CentrePublic Health OntarioUniversity of TorontoToronto Public Health
FundersUniversity of North Carolina at Chapel HillNational Institute for Health and Care Research
KeywordsLung cancerLungClinical trialMedicineOncologyInternal medicine

Abstract

fetched live from OpenAlex

Abstract Importance The relevance of randomized clinical trials (RCTs) outcomes to real-world settings – especially across countries – is sometimes limited by their restrictive eligibility criteria and variations in standards of care compared to routine clinical practice. Objective To assess the transportability of findings from the RCT Lung-MAP S1400I to real-world populations in the United States (US), Germany and France. Design This empirical validation study used patient-level data from the RCT Lung-MAP S1400I to build a transportability model to adjust for differences in patient characteristics from real-world target patient populations. Two sets of adjustments were performed – one limited to the set of measured clinical variables, and the second additionally including external information drawn from published literature and substantive knowledge on patient subgroups excluded from the trial. The latter enabled transportability to a significantly more diverse and representative real-world patient population by relaxing the stringent exclusion criteria used in Lung-MAP S1400I. For benchmarking, we compared how well the transportability analysis approximated observed overall survival in the respective real-world cohorts. Setting Observational study. Participants Eligible individuals diagnosed with advanced or metastatic NSCLC and previously treated with systemic therapy. Intervention/exposure Nivolumab monotherapy. Main outcome measures Overall survival. Results Sample size for the nivolumab arm in Lung-MAP S1400I was 127 and ranged from 133 to 1051 for the various real-world cohorts included. Patients with ECOG scores of 2+, index cancer stage ALK / EGFR mutations, presence of comorbidities and prior exposure to immunotherapy/targeted therapies were excluded from Lung-MAP S1400I, were but were eligible to receive nivolumab monotherapy in real-world care. Adjusting for measured clinical differences improved alignment of patient outcomes in the RCT and the real-world cohorts. However, only when variables related to excluded patient groups were also addressed did the results fully satisfy control conditions, yielding the closest approximation to real-world survival in the US, Germany, and France (mean discrepancy: 0.27 months over ∼30 months). Conclusions Overall survival in a more diverse real-world patient population could be extrapolated using data from the Lung-MAP S1400I trial when complemented with external information about excluded patient groups.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame machine prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.

metaresearch head score (Codex)0.348
metaresearch head score (Gemma)0.589
Version: metacan-v3-hybrid-931329e0061cValidation status: machine_predicted_unvalidated
Candidate categoriesMetaresearch
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.348
Threshold uncertainty score0.804

Distilled classifier scores by category (both heads)

CategoryCodexGemma
Metaresearch0.3480.589
Meta-epidemiology (narrow)0.0010.001
Meta-epidemiology (broad)0.0020.007
Bibliometrics0.0030.006
Science and technology studies0.0010.004
Scholarly communication0.0060.005
Open science0.0030.006
Research integrity0.0030.004
Insufficient payload (model declined to judge)0.0060.001

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.170
GPT teacher head0.556
Teacher spread0.386 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.

Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations0
Published2025
Admission routes1
Has abstractyes

Explore more

Same venuemedRxiv→Same topicLung Cancer Treatments and Mutations→French-language works237,207→